Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
200actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-21 | actual | When the study began enrolling |
| Primary completion | 2025-12-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-27 | actual | The whole study's end, after follow-up |
| First posted | 2026-06-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cancer
Interventions
- Drug: Nivolumab
- Combination product: Subcutaneous nivolumab combined with hyaluronidase
Primary outcomes
what the primary-completion date above is the date OFParticipant age
measured Baseline
Participant sex
measured Baseline
Participant race
measured Baseline
Participant ethnicity
measured Baseline
Body mass index (kg/m²)
measured Baseline
Smoking status
measured Baseline
Cancer diagnosis
measured Baseline
Disease stage at initial diagnosis (Stage 0-IV, unknown)
measured Baseline
Eastern Cooperative Oncology Group (ECOG) performance status distribution (0-4, unknown)
measured Baseline
Number of participants by tumor histology categories as applicable for each disease type, including unknown.
measured Baseline
Duration of therapy (days)
measured Up to 6 months
Duration of planned therapy (days)
measured Up to 6 months
Dose administered at index (mg)
measured Baseline
Concomitant anti-cancer therapy use
measured Baseline
Location of injection site (thigh or abdomen)
measured Up to 6 months
Number of participants with treatment switches or discontinuation.
measured Up to 6 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed